Robeco Institutional Asset Management B.V. Boosts Stake in United Therapeutics Corporation $UTHR

Robeco Institutional Asset Management B.V. raised its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 3.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 234,639 shares of the biotechnology company’s stock after acquiring an additional 8,352 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.52% of United Therapeutics worth $67,424,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of UTHR. Vaughan Nelson Investment Management L.P. acquired a new position in shares of United Therapeutics during the first quarter worth about $101,354,000. Nuveen LLC acquired a new position in shares of United Therapeutics during the first quarter worth about $83,533,000. Amundi lifted its stake in shares of United Therapeutics by 198.8% during the first quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock worth $107,635,000 after purchasing an additional 232,988 shares in the last quarter. Acadian Asset Management LLC lifted its stake in shares of United Therapeutics by 1,657.8% during the first quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company’s stock worth $55,217,000 after purchasing an additional 169,010 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of United Therapeutics by 46.1% during the first quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company’s stock worth $143,381,000 after purchasing an additional 146,664 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of recent research reports. Jefferies Financial Group boosted their price objective on United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Royal Bank Of Canada initiated coverage on United Therapeutics in a research note on Friday, September 26th. They set an “outperform” rating and a $569.00 price objective on the stock. UBS Group boosted their price target on United Therapeutics from $560.00 to $580.00 and gave the stock a “buy” rating in a research note on Monday. Bank of America boosted their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Finally, Cantor Fitzgerald boosted their price target on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Ten research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $449.57.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $421.80, for a total transaction of $9,490,500.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $434.88, for a total value of $1,739,520.00. Following the sale, the chief executive officer owned 130 shares in the company, valued at $56,534.40. The trade was a 96.85% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 238,435 shares of company stock valued at $93,353,482 over the last three months. Company insiders own 10.30% of the company’s stock.

United Therapeutics Stock Up 1.2%

Shares of NASDAQ UTHR opened at $443.44 on Friday. The stock’s 50 day moving average price is $353.34 and its two-hundred day moving average price is $318.06. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $444.57. The stock has a market capitalization of $20.00 billion, a P/E ratio of 17.31, a PEG ratio of 6.68 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same quarter in the previous year, the company earned $5.85 EPS. The company’s quarterly revenue was up 11.7% compared to the same quarter last year. On average, analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.